Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 3,664 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: sample collection Clear all
Recruiting Phase 1 Interventional

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

NCT06543381
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Olutasidenib
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Duarte, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 7:05 AM EDT
Recruiting Phase 2 Interventional

Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma

NCT06078709
View directory record Official record
Conditions
Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Esophagogastroduodenoscopy, Fluorouracil, Hypofractionated Radiation Therapy, Leucovorin Calcium, Oxaliplatin, Positron Emission Tomography, Survey Administration, Docetaxel, Durvalumab
Procedure · Drug · Radiation + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 7:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reducing Colorectal Cancer Death Through Mailed Outreach Screening

NCT02584998
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Mailed-FIT, Screening invitation-reminder
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 74 Years
Enrollment
782 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2018 · Synced Oct 23, 2026, 7:05 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Human Epididymis Protein 4 in Normal Menstruating Women

NCT01337999
View directory record Official record
Conditions
Healthy Premenopausal Women
Interventions
blood draws
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 23, 2026, 7:05 AM EDT
Completed No phase listed Observational Results available

Concept Mapping as a Scalable Method for Identifying Patient-Important Outcomes

NCT02792777
View directory record Official record
Conditions
Concept Mapping Versus Interviews
Interventions
Interviews, Concept Mapping (CM)
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 23, 2026, 7:05 AM EDT
Completed No phase listed Observational

Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)

NCT01475149
View directory record Official record
Conditions
Antiphospholipid Syndrome, Thrombophilia Due to Antiphospholipid Antibody, Systemic Lupus Erythematosus
Interventions
Phlebotomy
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 23, 2026, 7:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genes and Environment in Multiple Sclerosis

NCT01353547
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2040
U.S. locations
5
States / cities
Bethesda, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 23, 2026, 7:05 AM EDT
Completed No phase listed Observational

The Role of JAK2 in Alveolar Macrophages (AM's) in Chronic Beryllium Disease (CBD)

NCT02596347
View directory record Official record
Conditions
Chronic Beryllium Disease (CBD), Beryllium Sensitization (BeS)
Interventions
Blood draw, bronchoscopy
Procedure
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 23, 2026, 7:05 AM EDT
Recruiting Phase 2 Interventional

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

NCT06860815
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver
Interventions
Biopsy, Biospecimen Collection, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging, Transarterial Radioembolization, Yttrium Y 90 Resin Microspheres
Procedure · Biological · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 23, 2026, 7:05 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

NCT05411094
View directory record Official record
Conditions
Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Olaparib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Irvine, California • Los Angeles, California • Orange, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 23, 2026, 7:05 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

NCT04458922
View directory record Official record
Conditions
Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma, Metastatic Clear Cell Sarcoma of Soft Tissue, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 23, 2026, 7:05 AM EDT
Not listed No phase listed Observational

Overdose Risk Management and Naloxone

NCT03933345
View directory record Official record
Conditions
Opioid Use
Interventions
Study provides naloxone to participants who wish to have it. Not required to accept naloxone and no control.
Other
Lead sponsor
National Development and Research Institutes, Inc.
Other
Eligibility
18 Years and older
Enrollment
600 participants
Timeline
2019 – 2023
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 23, 2026, 7:05 AM EDT
Recruiting Phase 2 Interventional

Ivonescimab for the Treatment of Thymic Cancer

NCT06980077
View directory record Official record
Conditions
Thymus Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ivonescimab, Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Davis, California • Irvine, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 7:05 AM EDT
Recruiting Phase 3 Interventional

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

NCT07321652
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions
Zanubrutinib, Sonrotoclax, Computed Tomography, Bone Marrow Aspiration, Biospecimen Collection, Survey Administration
Drug · Procedure · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
65 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
224
States / cities
Birmingham, Alabama • Anaheim, California • Baldwin Park, California + 180 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 7:05 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection

NCT03366493
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia Grade 2/3
Interventions
FRD, Cytology, HPV testing, Colposcopy, ECC, Biospy
Combination Product · Other · Procedure
Lead sponsor
GY Highland Biotech LLC
Industry
Eligibility
20 Years to 60 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 23, 2026, 7:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stool Microbiome, Pathogens, and Infectious Agents Among Olympic and Elite Athletes

NCT02818413
View directory record Official record
Conditions
Athletic Performance
Interventions
Biospecimen collection and questionnaires
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 23, 2026, 7:05 AM EDT
Completed No phase listed Observational

Peripheral Immunologic Response of Solid Organ Transplant Recipients to Depletion Versus Non-depletion Protocols

NCT00839709
View directory record Official record
Conditions
Liver Disease, Liver Transplantation
Interventions
blood sampling
Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 3, 2011 · Synced Oct 23, 2026, 7:05 AM EDT
Recruiting Phase 2 Interventional

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

NCT07605416
View directory record Official record
Conditions
Plasma Cell Leukemia
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
10
States / cities
New Haven, Connecticut • North Haven, Connecticut • Baton Rouge, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 7:05 AM EDT
Recruiting Phase 3 Interventional

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

NCT07000084
View directory record Official record
Conditions
Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions
BCG Solution, Biopsy of Bladder, Cystoscopy, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Transurethral Resection of Bladder Tumor, Gemcitabine
Biological · Procedure · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
60
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 7:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

ReSET Aim 1b: Restarting Safe Education and Testing for Children With Medical Complexity - COVID-19 Testing in School With Children and Staff

NCT04899245
View directory record Official record
Conditions
Children With Medical Complexity (CMC), COVID-19
Interventions
BinaxNOW Rapid Antigen System
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 23, 2026, 7:05 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Inducing Self-Dehumanization to Examine Oxytocin and Suicide Risk

NCT06710964
View directory record Official record
Conditions
Mechanistic Self-Dehumanization Condition, Control Condition
Interventions
The Ten Item Personality Inventory, Mechanistic Self-Dehumanization Condition, Debrief, Control Condition, Clinical Interview, Self-Report Measures, Blood Draw
Other · Diagnostic Test
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 23, 2026, 7:05 AM EDT
Recruiting No phase listed Observational

TSC Biosample Repository and Natural History Database

NCT05676099
View directory record Official record
Conditions
Tuberous Sclerosis, Lymphangioleiomyomatosis
Interventions
Phlebotomy, Buccal (cheek) swab, Genetic Testing, Tissue donation after routine clinical procedure
Procedure · Genetic · Other
Lead sponsor
National Tuberous Sclerosis Association
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2050
U.S. locations
24
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 23, 2026, 7:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes

NCT02198092
View directory record Official record
Conditions
Familial Adenomatous Polyposis, Map Syndrome, Lynch Syndrome, Hnpcc, Colorectal Cancer
Interventions
Epi proColon Testing
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 23, 2026, 7:05 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

NCT04750954
View directory record Official record
Conditions
Neuroendocrine Neoplasm
Interventions
Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Duarte, California • Miami, Florida • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 23, 2026, 7:05 AM EDT